Prestige sumer Healthcare (PBH) - 2025 Q3 - Quarterly Results

Revenue Performance - Reported revenues for Q3 fiscal 2025 were $290.3 million, an increase of 2.7$282.7 million in Q3 fiscal 2024[3] - For the first nine months of fiscal 2025, revenues totaled $841.2 million, a decrease of 0.8$848.4 million in the same period last year[5] - The North American OTC Healthcare segment reported revenues of $238.9 million in Q3 fiscal 2025, a 1.0$236.6 million in the prior year[11] - International OTC Healthcare segment revenues for Q3 fiscal 2025 were $51.4 million, an increase of 11.3$46.2 million in the prior year[13] - Total segment revenues for the three months ended December 31, 2024, reached $290,317 thousand, a 2.7$282,741 thousand in the same period of 2023[31] - Non-GAAP Organic Revenues for the three months ended December 31, 2024, were $290,317 thousand, with a revenue change of 2.3$61.0 million, compared to $53.0 million in the prior year, with diluted earnings per share of$1.22, up approximately 15% from $1.06[4] - Net income for the nine months ended December 31, 2024, was$164,477 thousand, up from $159,881 thousand in the same period of 2023, representing a growth of 1.0$61,032,000, compared to $53,046,000 in Q4 2023, representing a 18.7$4.58, with a projected Non-GAAP Adjusted Diluted EPS of $4.50 after a normalized tax rate adjustment[42] Cash Flow and Investments - Non-GAAP free cash flow for Q3 fiscal 2025 was$63.5 million, down from $69.5 million in the prior year[9] - Cash and cash equivalents increased to$50,874 thousand at the end of the period, up from $46,469 thousand at the beginning of the period[29] - Non-GAAP Free Cash Flow for Q4 2024 was$63,525,000, compared to $69,476,000 in Q4 2023, indicating a decrease of 8.4$250,000,000, leading to a projected Non-GAAP Free Cash Flow of $240,000,000 after accounting for property and equipment additions[43] Debt and Liabilities - The company's net debt position as of December 31, 2024, was approximately$0.9 billion, resulting in a leverage ratio of 2.5x[10] - Total liabilities decreased to $1,541,064 thousand as of December 31, 2024, from$1,663,333 thousand on March 31, 2024, a reduction of 7.3%[27] - Interest paid decreased to $37,427 thousand for the nine months ended December 31, 2024, down from$49,666 thousand in the same period of 2023[29] - Interest expense decreased to $11,455,000 in Q4 2024 from$16,575,000 in Q4 2023, a reduction of 30.5%[40] Operational Performance - Operating income for the nine months ended December 31, 2024, was $248,347 thousand, compared to$260,276 thousand in the same period of 2023, reflecting a decrease of 4.6%[34] - Gross profit for the nine months ended December 31, 2024, was $464,453 thousand, compared to$472,631 thousand in the same period of 2023, indicating a decrease of 1.7%[34] - Non-GAAP EBITDA for Q4 2024 was $98,477,000, up from$93,796,000 in Q4 2023, reflecting a 5.7% growth[40] - Non-GAAP EBITDA Margin improved to 33.9% in Q4 2024 from 33.2% in Q4 2023[40] Share Repurchase - The company repurchased approximately 0.6 million shares for a total investment of approximately $40.2 million in the first nine months of fiscal 2025[10] - The company repurchased common stock amounting to$40,196 thousand during the nine months ended December 31, 2024[29] Future Outlook - The company raised its full-year fiscal 2025 earnings outlook, projecting revenues between $1,128 million and$1,132 million[17] - The company anticipates approximately 1% organic revenue growth for fiscal 2025[15]